Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
Explore this paper's citation graph
Summary
Topiramate alone and in combination with low‐dose amantadine may allow better reduction of dyskinesia with no adverse motor effects, and this effect was confirmed in the MPTP‐lesioned nonhuman primate, with a selective reduction in “bad on‐time.”
- Type
- article
- Published
- 2011-11-01
- Cited by
- 50
- References
- 64
- OpenAlex
- https://openalex.org/W2011503760
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3484947
Keywords
Amantadine, Dyskinesia, Topiramate, Pharmacology, Parkinson's disease
References
- Topiramate reduces AMPA‐induced Ca2+ transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures
- Modulation of AMPA Receptors in Cultured Cortical Neurons Induced by the Antiepileptic Drug Levetiracetam
- Calcium‐permeable AMPA receptors are involved in the induction and expression of l‐DOPA‐induced dyskinesia in Parkinson’s disease
- Molecular mechanisms of l-DOPA-induced dyskinesia.
- Topiramate modulation of kainate‐induced calcium currents is inversely related to channel phosphorylation level
- Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity
- Amantadine for dyskinesia in Parkinson's disease.
- L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
- Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia
- Subunit selectivity of topiramate modulation of heteromeric GABA(A) receptors.
- The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
- Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease
- Coexpression of striatal dopamine receptor subtypes and excitatory amino acid subunits
- AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
- Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment.
- Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.
- In vivo microdialysis and liquid chromatography/thermospray mass spectrometry of the novel anticonvulsant 2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate (topiramate) in rat brain fluid.
- Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
- Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test.
- Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
Cited by
- Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.
- Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches.
- Consumption of Pharmaceuticals in Primary Non-Alzheimer’s Degenerative Dementias
- Role for the nicotinic cholinergic system in movement disorders; therapeutic implications
- Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
- Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease.
- Modeling dyskinesia in animal models of Parkinson disease.
- Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats
- Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model
- Advances in non-dopaminergic treatments for Parkinson's disease
- Targeting glutamatergic synapses in Parkinson's disease.
- The Role of the Subthalamic Nucleus in L-DOPA Induced Dyskinesia in 6-Hydroxydopamine Lesioned Rats
- IRC-082451, a Novel Multitargeting Molecule, Reduces L-DOPA-Induced Dyskinesias in MPTP Parkinsonian Primates
- Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson’s disease
- Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.
- Animal models of L-DOPA-induced dyskinesia: an update on the current options.
- Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
- NMDA antagonists as Parkinson's disease therapy: disseminating the evidence.
- α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage
- Glutamatergic Receptors in Parkinson’s Disease
Related papers
- Dyskinesias induced by subthalamotomy in Parkinson’s disease are unresponsive to amantadine
- Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.
- Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
- Beneficial effects of amantadine on L‐dopa‐induced dyskinesias in Parkinson's disease
- The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
- [Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
- P2.109 Piclozotan reduces dyskinesia and OFF time in Parkinson's disease (PD) patients with L-dopa induced motor complications
- Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial